EcoDrugPlus

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSMPUG00000018485
Gene Symbol: P2RY4
2 Cross references
165 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSMPUG00000009759
Gene Symbol: P2RY6
2 Cross references
182 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSMPUG00000000099
Gene Symbol: RAMP1
2 Cross references
253 Possible Orthologues:

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSMPUG00000000454
Gene Symbol: RIPK1
2 Cross references
197 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSMPUG00000011950
Gene Symbol: RPTOR
2 Cross references
209 Possible Orthologues:

Renin

Ensembl ID : ENSMPUG00000011668
Gene Symbol: REN
2 Cross references
218 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSMPUG00000017277
Gene Symbol: RET
2 Cross references
204 Possible Orthologues:

Retinoic Acid Receptor Alpha

Ensembl ID : ENSMPUG00000014863
Gene Symbol: RARA
2 Cross references
331 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSMPUG00000012126
Gene Symbol: RARB
4 Cross references
450 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSMPUG00000006113
Gene Symbol: RARG
2 Cross references
445 Possible Orthologues:

Retinoid X Receptor Alpha

Ensembl ID : ENSMPUG00000012176
Gene Symbol: RXRA
4 Cross references
244 Possible Orthologues:

Retinoid X Receptor Beta

Ensembl ID : ENSMPUG00000002273
Gene Symbol: RXRB
2 Cross references
234 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).